no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
1 |
Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma
|
Kerbel, Robert S |
|
|
398 |
10297 |
p. 278-279 |
article |
2 |
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
|
Redjoul, Rabah |
|
|
398 |
10297 |
p. 298-299 |
article |
3 |
A strategy to reduce the carbon footprint of clinical trials
|
Adshead, Fiona |
|
|
398 |
10297 |
p. 281-282 |
article |
4 |
A time of crisis for the opioid epidemic in the USA
|
The Lancet, |
|
|
398 |
10297 |
p. 277 |
article |
5 |
Cheryl Moyer: egalitarian in global health research
|
Clark, Jocalyn |
|
|
398 |
10297 |
p. 291 |
article |
6 |
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|
Berdeja, Jesus G |
|
|
398 |
10297 |
p. 314-324 |
article |
7 |
Contrast-associated acute kidney injury in a patient with lower respiratory tract infection
|
Cichowitz, Cody |
|
|
398 |
10297 |
p. 340 |
article |
8 |
FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?
|
Jafar, Tazeen H |
|
|
398 |
10297 |
p. 283-284 |
article |
9 |
Five priorities for universal COVID-19 vaccination
|
Abecassis, Adrien |
|
|
398 |
10297 |
p. 285-286 |
article |
10 |
Helen Mae Murray Free
|
Watts, Geoff |
|
|
398 |
10297 |
p. 296 |
article |
11 |
Heterogeneity of treatment effects in malignant pleural mesothelioma
|
Di Maio, Massimo |
|
|
398 |
10297 |
p. 301-302 |
article |
12 |
Heterogeneity of treatment effects in malignant pleural mesothelioma – Authors' reply
|
Baas, Paul |
|
|
398 |
10297 |
p. 302 |
article |
13 |
Inquest begins over South African mental health failings
|
Scher, Marion |
|
|
398 |
10297 |
p. 288 |
article |
14 |
Lack of medicines in Mexico
|
Agren, David |
|
|
398 |
10297 |
p. 289-290 |
article |
15 |
Mass infection is not an option: we must do more to protect our young
|
Gurdasani, Deepti |
|
|
398 |
10297 |
p. 297-298 |
article |
16 |
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
|
Chen, Yu-Pei |
|
|
398 |
10297 |
p. 303-313 |
article |
17 |
Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study
|
|
|
|
398 |
10297 |
p. 325-339 |
article |
18 |
Paediatric surgery for congenital anomalies: the next frontier for global health
|
Stokes, Sarah C |
|
|
398 |
10297 |
p. 280-281 |
article |
19 |
Past and present women pioneers in biomedical science
|
Marks, Lara |
|
|
398 |
10297 |
p. 293-295 |
article |
20 |
Physical punishment and child outcomes: a narrative review of prospective studies
|
Heilmann, Anja |
|
|
398 |
10297 |
p. 355-364 |
article |
21 |
Portrait or snapshot?
|
Kneebone, Roger |
|
|
398 |
10297 |
p. 292 |
article |
22 |
Pre-eclampsia
|
Chappell, Lucy C |
|
|
398 |
10297 |
p. 341-354 |
article |
23 |
Social unrest disrupts South African health care
|
Makoni, Munyaradzi |
|
|
398 |
10297 |
p. 287 |
article |
24 |
The nutrition agenda must include tobacco control
|
Klein, Jonathan D |
|
|
398 |
10297 |
p. 300-301 |
article |
25 |
The nutrition agenda must include tobacco control – Authors' reply
|
Victora, Cesar G |
|
|
398 |
10297 |
p. 301 |
article |
26 |
Tocilizumab in COVID-19 therapy: who benefits, and how?
|
Yang, Chengliang |
|
|
398 |
10297 |
p. 299 |
article |
27 |
Tocilizumab in COVID-19 therapy: who benefits, and how?
|
Neumann, Avidan U |
|
|
398 |
10297 |
p. 299-300 |
article |
28 |
Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
|
Horby, Peter |
|
|
398 |
10297 |
p. 300 |
article |